“Medical tourism sits at the intersection of healthcare, trade and economic development. Over the next three to five years, China’s inbound medical tourism will experience rapid expansion. China is confident and capable of becoming a leading global medical‑tourism destination,” Dr. Hsiang concluded.

In traditional oncology, the "trial-and-error" method has long been a frustrating reality for patients. Clinicians prescribe standard chemotherapy and targeted regimens based on global guidelines.Today, a revolutionary technology known as Organoid Drug Sensitivity Testing is dismantling this paradigm. By cultivating a patient's micro-scale "biological avatar" in the laboratory, clinicians can pre-screen and predict the most effective drug combination before administration.